Assays capable of detecting TRPML1 modulators for drug discovery

By Molly Rowlett, Industrial Placement Student, University of Bristol

We generated a stable cell line expressing the lysosomal channel TRPML1 at the cell surface. First we validated this on manual patch-clamp and went on to develop robust assays for our higher throughput screening platforms, Qube 384 and FLIPR Penta, which are capable of detecting TRPML1 modulators for drug discovery.

Read our poster 'Development of TRPML1-4A assays across manual, automated patch-clamp, and fluorescence-based platforms' as presented at the Cambridge Ion Channels Forum last week.

We generated a stable cell line expressing the lysosomal channel TRPML1 at the cell surface. First we validated this on manual patch-clamp and went on to develop robust assays for our higher throughput screening platforms, Qube 384 and FLIPR Penta, which are capable of detecting TRPML1 modulators for drug discovery.

Read our poster 'Development of TRPML1-4A assays across manual, automated patch-clamp, and fluorescence-based platforms' as presented at the Cambridge Ion Channels Forum last week.

We generated a stable cell line expressing the lysosomal channel TRPML1 at the cell surface. First we validated this on manual patch-clamp and went on to develop robust assays for our higher throughput screening platforms, Qube 384 and FLIPR Penta, which are capable of detecting TRPML1 modulators for drug discovery.

Read our poster 'Development of TRPML1-4A assays across manual, automated patch-clamp, and fluorescence-based platforms' as presented at the Cambridge Ion Channels Forum last week.

Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram